OGT awarded SBRI contract to develop innovative NGS analysis software

OGT awarded SBRI contract to develop innovative NGS analysis software

Monday 21 July 2014

Oxford Gene Technology (OGT), the molecular genetics company, today announced it has been awarded a £200K phase one development contract by the Small Business Research Initiative (SBRI) healthcare competition.

The contract is to develop whole genome Next Generation Sequencing (NGS) analysis software to increase the accuracy, and enhance the analysis of genomic sequence data. This landmark project has the potential to accelerate the diagnosis of cancer and rare diseases, ultimately supporting patient care and research.

The SBRI is a collaboration between the UK Department of Health and Genomics England Ltd. The initiative operates a competition for funding designed to support the development of innovative technologies that address the requirements of the 100K Genome Project. This includes bioinformatics and analysis algorithms, through to the development of new commercial products for genomic screening and stratified medicine. The contracts are awarded in two phases; the first enables companies to demonstrate the technical feasibility of their product and if successful, they are eligible for a second phase of funding to develop and test the product further.

OGT has considerable experience gained in the design and development of its class-leading software for microarray and NGS data interpretation. The Company will apply this knowledge to develop a clinician-friendly interpretation package for whole genome scale genetic variant data.

Dr Mike Evans, CEO of OGT said: "The award of this contract demonstrates our position at the forefront of NGS data analysis and clinical interpretation plus our ability to rapidly commercialise a resulting product using our extensive international sales and marketing infrastructure. This software will significantly enhance the ability of clinicians to understand and make use of patient genomic data, allowing the delivery of truly personalised medicine."

For more information, please contact:

Oxford Gene Technology

Stephen Archibald, Director of Communications
T: +44 (0) 1865 856826
F: +44 (0) 1865 848684
E: [email protected]
W: www.ogt.com

Instinctif Partners (PR Agency for OGT)

Melanie Toyne Sewell / Jen Lewis
T: +44 (0) 20 7457 2029
E: [email protected]


Notes for Editors:

About the Small Business Research Initiative (SBRI) healthcare competition

The Department of Health and Genomics England Limited are collaborating to launch a new Small Business Research Initiative (SBRI) competition to find enabling technologies for genomics sequence data analysis and interpretation. The focus of this competition will be on innovative technologies that address the requirements of the 100k Genome Project. These technologies may include developments in the areas of bioinformatics, software pipelines, computer hardware and analysis algorithms. The Department of Health is investing up to £10m in this competition, which will be managed by Genomics England Limited and which is expected to run in two phases.

For more information, visit www.sbrihealthcare.co.uk

About the 100K Genome Project
Genomics England is a company owned by the Department of Health and was set up to deliver the 100,000 Genomes Project. This project will sequence 100,000 whole genomes from NHS patients by 2017. The project is focusing on patients with rare diseases, and their families, as well as patients with common cancers. The project is currently in its pilot phase and it is expected that a lot will be learnt during this time to inform the next stages. Genomics England was announced by Jeremy Hunt, Secretary of State for Health, as part of the NHS 65th birthday celebrations on 5 July 2013.

For more information, visit www.genomicsengland.co.uk

About Oxford Gene Technology
Oxford Gene Technology (OGT) provides world-class genetics research solutions to leading clinical and academic research institutions. Founded by Professor Sir Edwin Southern, and with customers in over 60 countries worldwide, OGT has a strong reputation and increasing share in the large and growing genomic medicine market. The Company's Cytocell®, CytoSure™, SureSeq™ and Genefficiency™ range of fluorescence in situ hybridisation (FISH), microarray and next generation sequencing (NGS) products and services deliver high-quality genetic analysis, enabling accurate identification and confirmation of the causative variation underlying genetic disease.

For more information on the Company, please visit our website at www.ogt.com.

CytoSure™ and Genefficiency™ NGS browser/report: For Research Use Only; Not for Use in Diagnostic Procedures